articleJournal of Clinical OncologyMay 3, 2005Closed access

Long-Term Results of the R-CHOP Study in the Treatment of Elderly Patients With Diffuse Large B-Cell Lymphoma: A Study by the Groupe d'Etude des Lymphomes de l'Adulte

PFPierre FeugierAVAmbro van HoofCSCatherine SebbanPSP. Solal-CélignyRBRéda Bouabdallah

Centre Hospitalier Universitaire de Lille · Centre Hospitalier Universitaire Henri-Mondor · +3 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

PURPOSE: To analyze the long-term outcome of patients included in the Lymphome Non Hodgkinien study 98-5 (LNH98-5) comparing cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) to rituximab plus CHOP (R-CHOP) in elderly patients with diffuse large B-cell lymphoma. PATIENTS AND METHODS: LNH98-5 was a randomized study that included 399 previously untreated patients, age 60 to 80 years, with diffuse large B-cell lymphoma. Patients received eight cycles of classical CHOP (cyclophosphamide 750 mg/m(2), doxorubicin 50 mg/m(2), vincristine 1.4 mg/m(2), and prednisone 40 mg/m(2) for 5 days) every 3 weeks. In R-CHOP, rituximab 375 mg/m(2) was administered the same day as CHOP. Survivals were analyzed…

Citation impact

1,498
total citations
FWCI
54.18
Percentile
100%
References
27
Citations per year

Authors

16

Topics & keywords

Topics
Keywords
  • Medicine
  • Vincristine
  • CHOP
  • Rituximab
  • International Prognostic Index
  • Prednisone
  • Internal medicine
  • Lymphoma
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.